Alzheimer's Disease robs a person's memory and becomes more debilitating as it progresses.
While there is no known cure, the National Institutes of Health is sponsoring a large-scale clinical trial to find out if an experimental drug can be used to prevent the disease.
It's called Solanezumab and is designed to rid the brain of plaques and a protein called Amyloid associated with Alzheimer's.
Researchers will enroll older individuals for the study who have evidence of that protein marker in their brains, but do not yet show clinical symptoms of the disease.
They hope to show that by starting treatment in high risk individuals before any symptoms are present, and by treating them for longer periods of time, loss of memory will be reduced and ultimately prevent development of Alzheimer's Disease.
The study is expected to take three years.